LivaNova LIVN Cardiopulmonary — Selling, general, and administrative

Other segment segments

Similar metrics at other companies

MDTCardiovascular — Selling, general, and administrative expense

$1.19B+17.4%

BSXCardiovascular — Selling, general and administrative expenses

$959M+9.9%

BSXCardiovascular — Selling, general and administrative expenses, percentage of net sale

27.4%-0.3pp

ASHPersonal Care And Household — Selling General And Administrative Expense

$21M0.0%

CCAdvanced Performance Materials — Selling General And Administrative Expense

$34M+3.0%

WHDPressure Control — Selling, general, administrative expenses and other

$38.1M+118%

Questions, answered.

What is LivaNova's cardiopulmonary — selling, general, and administrative?

LivaNova (LIVN) reported cardiopulmonary — selling, general, and administrative of $59.85M in Q1 2026.

How has LivaNova's cardiopulmonary — selling, general, and administrative changed year-over-year?

LivaNova's cardiopulmonary — selling, general, and administrative increased by 2.3% year-over-year, from $58.48M to $59.85M.

What is the long-term trend for LivaNova's cardiopulmonary — selling, general, and administrative?

Over 3 years (2022 to 2025), LivaNova's cardiopulmonary — selling, general, and administrative has grown at a 10.9% compound annual growth rate (CAGR), from $168.6M to $229.78M.

What does cardiopulmonary — selling, general, and administrative mean?

Captures the indirect costs associated with operating the cardiopulmonary segment, including sales commissions, marketing, and general administrative overhead. It provides insight into the level of investment required to support and scale the segment's commercial activities.